A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...
Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...
Bernd Kasper, MD, PhD, provides an overview of the phase 3 DeFi trial of nirogacestat for the treatment of patients with progressing desmoid tumors.
Panelists discuss how optimizing shared-care models between academic and community centers enhances continuity in complex hematologic malignancies. Key monitoring parameters for tagraxofusp include ...
During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.
A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal ...
The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.
Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...
Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback